BLIN, Patrick; DUREAU-POURNIN, C.; COTTIN, Y.; BENICHOU, Jacques; MISMETTI, P.; ABOUELFATH, A.; LASSALLE, Regis; DROZ, C.; MOORE, Nicholas

doi:10.1002/cpt.1318

Metadatos

Mostrar el registro completo del ítem

Licencia de uso del documento

Idioma

Article de revue

Este ítem está publicado en

Clinical Pharmacology and Therapeutics. 2019, vol. 105, n° 6, p. 1439-1455

Resumen en inglés

Dabigatran and rivaroxaban at standard (SD) or reduced doses (RD) have been compared to warfarin in non-valvular atrial fibrillation (NVAF), but not to each other. This was a new user study of SD and RD dabigatran or rivaroxaban for NVAF in the French healthcare database, matched on gender, age, date of first dispensing, and high-dimensional propensity score, followed 2 years. Hazard ratios [95% Confidence Intervals] of stroke or systemic embolism (SSE), major bleeding (MB) or death, were computed. In matched SD patients (8,290 per arm), mean age 67, HR for dabigatran vs. rivaroxaban were SSE 0.92 [0.67-1.26], MB 0.59 [0.39-0.90], death 0.84 [0.65-1.11]. In RD patients (7639 per arm), mean age 80, HR for dabigatran vs. rivaroxaban were SSE 0.73 [0.59-0.94], MB 0.74 [0.57-0.96], death 0.95 [0.83-1.09]. In conclusion, at either dose dabigatran had similar or better effectiveness than rivaroxaban, but lower bleeding risk. Death rates were not different. This article is protected by copyright. All rights reserved.< Leer menos

Palabras clave en inglés

PharmacoEpi-Drugs

Metadatos

Compartir este ítem

Licencia de uso del documento

Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation

Idioma

Este ítem está publicado en

Resumen en inglés

Palabras clave en inglés

URI

DOI

Centros de investigación